Tools
Cobalt Toxicity
Introduction
Cobalt (atomic symbol Co) is a gray, ductile, magnetic element with atomic number 27 and atomic weight 58.9 Da. In the environment, cobalt occurs in naturally occurring minerals and is commonly combined with elements such as copper, nickel, manganese, arsenic, sulfur, and oxygen. Cobalt’s ferromagnetic properties, as well as high melting (1495.05 °C/ 2723.1 °F) and boiling (2927 °C/5312.6 °F) points, support its widespread industrial use in manufacturing hard metals and superalloys. The alloy Alnico, a blend of iron, aluminum, nickel, and cobalt, is valued for its permanent magnetic properties. Chronic occupational exposure often occurs during the production of tungsten carbide, which is utilized for its hardness, heat resistance, and mechanical strength.[1]
Historically, cobalt chloride (CoCl2) was used in medicine to treat anemia by promoting erythropoiesis.[2] Adverse effects, including thyroid dysfunction and goiter, led to the discontinuation of cobalt administration for this indication. Cyanocobalamin, otherwise known as vitamin B12, contains a trivalent cobalt ion (Co3+) and is a biochemically important cobalt compound. Vitamin B12 is an essential nutrient naturally present in foods of animal origin, including dairy, eggs, fish, poultry, and meat. Deficiency may result in pernicious anemia and peripheral neuropathy.[3] Hydroxocobalamin, a metabolic precursor, is employed as an antidote for cyanide poisoning and may have therapeutic potential in vasoplegic shock.[4] Potential exposure to cobalt occurs via oral, respiratory, and dermal routes.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Cobalt occurs in elemental, inorganic salt, and organic forms. Common sources of cobalt exposure include artist pigments (cobalt blue), dyes, porcelain, cement, rubber, superalloys, drill production, cutting tools, catalysts, orthopedic implants, dental hardware, vitamin supplementation, electroplating, outdated anemia treatments, and widia-steel production. However, exposure to pure elemental cobalt is primarily occupational and exerts toxicity via the respiratory route.[5] Inorganic salts, such as CoCl2 and cobaltous sulfate (CoSO4), are generally more toxic than organic cobalt. Organic cobalt exposure typically arises from ingestion of cyanocobalamin and demonstrates low toxicity due to minimal oral bioavailability.[6]
The single toxic dose of cobalt and its salts is unknown. In patients with the condition originally described as "beer drinker’s cardiomyopathy," reported cobalt intake averaged 6 to 8 mg of CoSO4 per day over weeks to months.[7] Severe toxicity developed in several patients, including multiple fatalities. In contrast, infants treated for anemia received 40 mg of CoCl2 per day for 3 months without clinically apparent adverse effects.[8] These observations indicate that additional factors influence the development of cobalt poisoning.[9]
Epidemiology
Historically, cobalt exposure occurred through the use of CoCl2 to treat anemia and through the consumption of beer containing CoSO4 as a foam stabilizer. Current sources of cobalt exposure include chemistry sets, dyes, metal mining and processing facilities, and orthopedic implants. The most significant potential source of exposure is the production of hard-metal tungsten carbide. Several epidemics of cobalt-induced goiter and cardiomyopathy were documented between 1950 and 1970.
The first identified cases of cardiomyopathy occurred in Nebraska in 1966, with 64 cases and 30 fatalities.[10][11] An additional 48 cases were reported in Quebec, with a mortality rate of 46%, and 20 cases in Minneapolis from 1964 to 1967, with a mortality rate of 43%.[12][13] Investigations determined that all cases were linked to beer containing added CoSO4 as a foam stabilizer. Affected populations primarily consisted of men who consumed beer daily, often up to 24 pints per day, and were malnourished.[14]
In the general population, nutritional supplements are the most common source of cobalt exposure.[15] Environmental contamination and secondary exposure may result from inadequate disposal practices at factories handling cobalt or tungsten carbide.[16] Tungsten carbide is produced by sintering powdered cobalt and tungsten at high temperatures (1550 °C/2822?°F) in the presence of hydrogen. Airborne concentrations of cobalt and tungsten in factories can reach levels 10 times ambient concentrations.[17]
Additional occupational exposures occur during the maintenance of hard-metal blades and diamond polishing.[18][19] Inhalation of aerosolized, dissolved, and ionized cobalt generated from cutting and polishing can lead to hard metal disease (HMD). Occupational asthma is frequently associated with cobalt exposure alone or in combination with tungsten carbide.[20] The incidence of HMD is poorly defined. In a case series, 5 of 320 patients presenting to an occupational respiratory clinic over 3 years were diagnosed with HMD.[21] Other reports describe 11 of 290 exposed workers with interstitial infiltrates on chest radiography and 22 cases of cobalt-induced asthma documented over 36 years.[22][23]
Recent concern has arisen regarding the use of cobalt salts by competitive athletes for “blood doping” to enhance performance through stimulation of erythropoiesis. Potential adverse effects render this method a high-risk and suboptimal approach to performance enhancement.[24] Metal-on-metal arthroplasties, including hip and knee implants, represent a contemporary source of cobalt toxicity. Blood cobalt concentrations increase following arthroplasty implantation, and implant failure can result in substantial elevations and systemic toxicity. Patients undergoing revision of ceramic-on-ceramic arthroplasties face an increased risk of third-body wear, which may accelerate the failure of metal-on-metal implants.[25]
Pathophysiology
Similar to other transition metals, cobalt toxicity affects multiple organ systems. Acute toxicity from excessive cobalt exposure produces endocrine, cardiovascular, metabolic, central and peripheral nervous system, gastrointestinal, and hematologic effects. Chronic inhalational exposure causes pulmonary disease, including occupational asthma and HMD.[26] Divalent cobalt (Co2+) resembles common intracellular cations such as calcium (Ca2+) and magnesium (Mg2+). Cobalt inhibits enzymes involved in protein and ribonucleic acid synthesis, including α-ketoglutarate dehydrogenase, α-lipoic acid, and dihydrolipoic acid.[27] Inhibition of these enzymes likely underlies cobalt-induced cardiomyopathy. CoCl2 inhibits tyrosine iodinase. This inhibition results in decreased levels of thyroid hormones (triiodothyronine and thyroxine) and hypothyroidism.[28]
Several mechanisms may account for the erythropoietic effects of CoCl2.[29] Cobaltous ions can bind to transferrin, impair oxygen delivery to renal cells by inducing hypoxia-inducible factor 1α, and increase iron availability for erythropoiesis. These effects lead to reticulocytosis and polycythemia.[30][31] Cobalt participates in redox cycling, generating excess free radicals that can cause tissue damage, likely contributing to pulmonary toxicity.[32] Dermatitis from cobalt likely represents a type IV hypersensitivity reaction, analogous to that caused by nickel.[33]
Histopathology
The histologic features of cobalt cardiomyopathy resemble those observed in cardiomyopathies arising from protein and thiamine deficiency.[34] In the mid-1960s, breweries began adding cobalt to beer as a foam stabilizer. Heavy beer consumers subsequently developed a distinct dilated cardiomyopathic syndrome termed "beer drinkers’ cardiomyopathy." Postmortem histology demonstrated vacuolization and cellular degeneration. Specific findings in cobalt cardiomyopathy included myocyte atrophy and myofibrillar loss.[35] Additional thyroid abnormalities in this patient cohort consisted of follicular cell changes and colloid depletion.[36]
In individuals with hard metal lung disease (HMLD), bronchoalveolar lavage revealed multinucleated giant cells and increased inflammatory cells.[37][38][39] These findings are consistent with desquamative giant cell interstitial pneumonitis (GIP). Early case series suggested that GIP is pathognomonic for HMLD.[40][41] More recent reports indicate that GIP may not be pathognomonic and that an immune-mediated etiopathogenesis could be involved.[42][43]
Arthroprosthetic cobaltism likely results from the development of metallosis and trunnionosis. "Metallosis" describes the deposition of metal particles from an implant into surrounding tissue due to abnormal wear.[44] "Trunnionosis" refers to metal erosion at the trunnion, the region where the femoral head implant connects to the neck of the arthroplasty.[45] Both processes indicate implant failure and increase the risk of systemic toxicity. Arthroprosthetic cobaltism frequently presents with aseptic lymphocyte-dominated vasculitis-associated lesions or pseudotumor formation.[46] Histologic features include lymphocytic invasion forming perivascular infiltrates. Gross findings may include discoloration of synovial fluid.[47]
Toxicokinetics
The bioavailability of cobalt varies widely across forms and is primarily based on animal studies. In humans, cobalt distribution is influenced by plasma proteins such as albumin and transferrin, which normally bind iron. Cellular uptake is mediated by the P2X7 transporter and occurs via divalent metal transporter 1.[48] Cobalt localizes to multiple organs, including the kidney, liver, heart, and spleen.[49]
Cobalt elimination occurs predominantly in the urine, with a smaller fraction excreted in the feces. Urinary elimination increases during acute exposures.[50] Elimination rates generally correlate with exposure patterns in occupational exposure studies. Urinary excretion increases at the end of a standard workweek compared to the beginning. Evidence indicates that excretion also rises immediately following cessation of exposure.[51][52]
History and Physical
Cobalt toxicity is a rare diagnosis, and clinical signs and symptoms overlap substantially with more common diseases. Clinical suspicion is required for diagnosis. Ingestion of cobalt salts or elemental cobalt can cause gastrointestinal distress, likely due to direct irritation of the gastrointestinal tract.[53] A complete history, including occupational, nutritional, and surgical information, is essential to identify potential sources of cobalt exposure. Heart failure findings are prominent in patients with cobalt-induced cardiomyopathy, including tachycardia, dyspnea, and evidence of fluid overload.
Occupational exposure in hard metal manufacturing and diamond polishing confers a markedly increased risk of toxicity, particularly HMLD. Affected individuals commonly present with dyspnea, cough, and wheezing.[54][55] Arthroprosthetic-associated cobalt toxicity may manifest with neurologic dysfunction, including peripheral neuropathy, ocular toxicity, and cognitive decline, as well as hypothyroidism and cardiomyopathy.[56]
Patients may report pain, swelling, and difficulty walking before severe toxicity develops, often occurring well after the initial surgery.[57] Dermatitis may also occur, particularly in occupational settings, as cobalt is a known sensitizer.[58] Case reports and current evidence indicate that cobalt does not appear to cause renal toxicity, teratogenicity, or impaired fertility.[59][60]
Evaluation
Early consultation with a poison control center or a medical toxicologist can guide diagnostic workup and management. Targeted testing can help confirm exposure and assess the severity of organ involvement. Body fluid testing for cobalt is not widely available, limiting the use of this assessment method in acute settings. Adjunctive laboratory tests that may indicate toxicity should guide acute care, including a complete blood count, reticulocyte count, erythropoietin level, and thyroid-stimulating hormone level. Severe cases may demonstrate metabolic acidosis and elevated lactate concentrations. Electrocardiograms, echocardiograms, and troponin measurements can assist in identifying cardiomyopathy.[61]
Urine cobalt levels are most commonly employed for occupational monitoring. Normal serum cobalt concentrations range from 0.1 to 1.2 mcg/L. The reference range for urinary cobalt is 0.1 to 2.2 mcg/L.[62][63] Interpretation of urinary levels requires consideration of exposure dose and duration, given variability in elimination kinetics. Whole-blood cobalt levels are considered the most accurate indicator of total-body burden.
Imaging can help identify individuals at high risk of developing toxicity if concerns for arthroprosthetic failure arise. Ultrasound and magnetic resonance imaging provide greater specificity and sensitivity for cobalt-containing implants.[64] Imaging does not diagnose cobalt toxicity but can detect local tissue reactions and implant failure.
Cardiac magnetic resonance imaging has recently been used to diagnose cobalt-induced cardiomyopathy in patients with metal-on-metal hip prostheses.[65] Chest radiography and computed tomography can identify pulmonary disease, particularly in the context of occupational exposures, although pulmonary toxicity may occur from other routes of exposure. Outpatient pulmonary function testing may reveal decreased vital capacity.[66][67][68]
Treatment / Management
Supportive care is the mainstay of treatment for cobalt toxicity. Acute presentations require prompt and aggressive decontamination and medical management. No specific studies address gastrointestinal decontamination in cobalt toxicity. Standard decontamination methods used for other metal toxicities, including whole bowel irrigation, are likely applicable, particularly when radioopaque material is visible on radiography. Gastric lavage may be beneficial for liquid ingestions but is less effective for solid forms. Antiemetics should be administered for nausea and vomiting.
Chelation therapy is poorly studied in humans, with most evidence derived from animal studies and case reports. Current data suggest that calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA) and N-acetylcysteine (NAC) are reasonable options. Although NAC is not a conventional chelating agent, the thiol group provides a binding site for cobalt.[69][70][71] Chelation has limited utility until the cobalt source is removed, for example, by arthroplasty removal.[72] Indications for chelation therapy include evidence of end-organ toxicity, such as severe acidosis or cardiac failure.(B3)
Prevention is the primary strategy for occupational exposures. Systems-based interventions, including improved ventilation, have markedly reduced toxicity associated with industrial exposures.[73] Patients with HMLD or cobalt-induced asthma may benefit from corticosteroids in addition to removal from the exposure source.
Differential Diagnosis
Acute cobalt toxicity is rare and most commonly occurs via ingestion. Presenting symptoms generally consist of gastrointestinal distress, which has a broad differential diagnosis. Diagnosis of cobalt poisoning can be challenging without an appropriate history. Poisonings with other metals may produce similar symptoms, emphasizing the need for a detailed exposure history.
Respiratory complaints should prompt consideration of pneumoconiosis in occupational settings, such as tungsten carbide manufacturing. Cobalt toxicity or HMLD should be included among potential causes. Occupational history helps rapidly narrow the etiology. Patients presenting with polycythemia or goiter should be evaluated for possible exposure to cobalt salts. Cardiomyopathy has a wide differential diagnosis. A surgical history of hip arthroplasty should raise suspicion for cobalt toxicity. Investigation of the specific implant type can aid in diagnosis and risk assessment.
Prognosis
Acute cobalt toxicity can cause severe illness. Cardiomyopathy associated with cobalt toxicity carries a high mortality rate. Data on chelation for nonarthroplastic cobalt toxicity are limited. Case reports suggest that chelation may improve recovery from cardiomyopathy in patients with arthroplastic cobalt toxicity.[74]
Prognosis in arthroprosthetic cobalt toxicity depends on early identification and timely arthroplasty revision. Revision reduces cobalt concentrations in blood and serum and is associated with clinical improvement.[75][76] Recovery likely correlates with the duration of exposure to elevated cobalt levels. In some cases, chelation after implant removal does not result in complete recovery. Persistent symptoms may include tinnitus, hearing loss, or cardiomyopathy requiring implantation of a left ventricular assist device.[77][78] Removal of the exposure source often leads to recovery in patients with HMLD.[79][80]
Complications
Delayed identification of cobalt toxicity can result in poor recovery and substantial morbidity. Manifestations include cardiomyopathy, peripheral neuropathy, vision loss, and chronic respiratory disease. Cobalt metal without tungsten carbide is classified by the International Agency for Research on Cancer as Group 2B, indicating that it is possibly carcinogenic to humans.[81] Cobalt in combination with tungsten carbide is classified as Group 2A, signifying that it is carcinogenic to humans. Human data are limited, but animal studies suggest an association with cancers, including soft tissue sarcomas and lung cancer.[82][83][84]
Deterrence and Patient Education
Cobalt toxicity most commonly occurs in the context of metal-on-metal arthroplasty or occupational exposure. Appropriate personal protective equipment and adherence to workplace safety guidelines are essential to minimize exposure to cobalt and tungsten carbide powders and debris. Reducing exposure reduces the risk of disease development. Patients with metal-on-metal hip arthroplasties should discuss concerns with their surgeon, particularly if new pain, swelling, or difficulty walking develops, as these factors increase the risk of toxicity from the implant.
Enhancing Healthcare Team Outcomes
Cobalt toxicity is a relatively rare diagnosis and can be challenging to identify in typical healthcare settings, such as emergency departments or outpatient clinics. Signs and symptoms of toxicity overlap with those of many more commonly diagnosed conditions. Primary care and emergency medicine clinicians are most likely to encounter patients with acute complaints.
Consultation with certified specialists in poison information, medical toxicologists, or clinical toxicologists at the nearest poison control center is essential for developing an optimal management plan. Expert guidance also supports education of the interprofessional team, reducing potential morbidity and mortality. Management of cobalt toxicity is primarily informed by case reports and animal studies. Epidemiologic data are available from several outbreaks and occupational exposures, particularly involving pulmonary disease such as HMLD. No randomized controlled trials exist regarding treatment.
References
Barceloux DG. Cobalt. Journal of toxicology. Clinical toxicology. 1999:37(2):201-6 [PubMed PMID: 10382556]
Level 3 (low-level) evidenceDuckham JM, Lee HA. The treatment of refractory anaemia of chronic renal failure with cobalt chloride. The Quarterly journal of medicine. 1976 Apr:45(178):277-94 [PubMed PMID: 940922]
Silverstein WK, Cheung MC, Lin Y. Vitamin B(12) deficiency. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2022 Jun 20:194(24):E843. doi: 10.1503/cmaj.220306. Epub [PubMed PMID: 35724997]
Kaiser SK, Dart RC. The Roles of Antidotes in Emergency Situations. Emergency medicine clinics of North America. 2022 May:40(2):381-394. doi: 10.1016/j.emc.2022.01.008. Epub 2022 Apr 5 [PubMed PMID: 35461629]
Swennen B, Buchet JP, Stánescu D, Lison D, Lauwerys R. Epidemiological survey of workers exposed to cobalt oxides, cobalt salts, and cobalt metal. British journal of industrial medicine. 1993 Sep:50(9):835-42 [PubMed PMID: 8398878]
Level 2 (mid-level) evidenceDevi S, Pasanna RM, Shamshuddin Z, Bhat K, Sivadas A, Mandal AK, Kurpad AV. Measuring vitamin B-12 bioavailability with [13C]-cyanocobalamin in humans. The American journal of clinical nutrition. 2020 Dec 10:112(6):1504-1515. doi: 10.1093/ajcn/nqaa221. Epub [PubMed PMID: 32844171]
Kesteloot H, Roelandt J, Willems J, Claes JH, Joossens JV. An enquiry into the role of cobalt in the heart disease of chronic beer drinkers. Circulation. 1968 May:37(5):854-64 [PubMed PMID: 5646867]
ROHN RJ, BOND WH. Observations on some hematological effects of cobalt-iron mixtures. The Journal-lancet. 1953 Aug:73(8):317-24 [PubMed PMID: 13096934]
Catalani S, Leone R, Rizzetti MC, Padovani A, Apostoli P. The role of albumin in human toxicology of cobalt: contribution from a clinical case. ISRN hematology. 2011:2011():690620. doi: 10.5402/2011/690620. Epub 2010 Oct 31 [PubMed PMID: 22084701]
Level 3 (low-level) evidenceLITTLE JA, SUNICO R. Cobalt-induced goiter with cardiomegaly and congestive failure. The Journal of pediatrics. 1958 Mar:52(3):284-8 [PubMed PMID: 13526084]
McDermott PH, Delaney RL, Egan JD, Sullivan JF. Myocardosis and cardiac failure in men. JAMA. 1966 Oct 17:198(3):253-6 [PubMed PMID: 4223885]
Morin YL, Foley AR, Martineau G, Roussel J. Quebec beer-drinkers' cardiomyopathy: forty-eight cases. Canadian Medical Association journal. 1967 Oct 7:97(15):881-3 [PubMed PMID: 6051256]
Level 3 (low-level) evidenceAlexander CS. Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty-eight cases. The American journal of medicine. 1972 Oct:53(4):395-417 [PubMed PMID: 4263183]
Level 3 (low-level) evidenceMorin Y, Daniel P. Quebec beer-drinkers' cardiomyopathy: etiological considerations. Canadian Medical Association journal. 1967 Oct 7:97(15):926-8 [PubMed PMID: 6051264]
Tvermoes BE, Unice KM, Paustenbach DJ, Finley BL, Otani JM, Galbraith DA. Effects and blood concentrations of cobalt after ingestion of 1 mg/d by human volunteers for 90 d. The American journal of clinical nutrition. 2014 Mar:99(3):632-46. doi: 10.3945/ajcn.113.071449. Epub 2014 Feb 5 [PubMed PMID: 24500148]
Abraham JL, Hunt A. Environmental contamination by cobalt in the vicinity of a cemented tungsten carbide tool grinding plant. Environmental research. 1995 Apr:69(1):67-74 [PubMed PMID: 7588496]
FAIRHALL LT, KEENAN RG, BRINTON HP. Cobalt and the dust environment of the cemented tungsten carbide industry. Public health reports (Washington, D.C. : 1896). 1949 Apr 15:64(15):485-90 [PubMed PMID: 18114620]
Linnainmaa M, Kangas J, Kalliokoski P. Exposure to airborne metals in the manufacture and maintenance of hard metal and stellite blades. American Industrial Hygiene Association journal. 1996 Feb:57(2):196-201 [PubMed PMID: 8615327]
Demedts M, Gyselen A. [The cobalt lung in diamond cutters: a new disease]. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie. 1989:51(6):559-81 [PubMed PMID: 2561412]
Kusaka Y, Iki M, Kumagai S, Goto S. Epidemiological study of hard metal asthma. Occupational and environmental medicine. 1996 Mar:53(3):188-93 [PubMed PMID: 8704860]
Level 2 (mid-level) evidenceMizutani RF, Terra-Filho M, Lima E, Freitas CS, Chate RC, Kairalla RA, Carvalho-Oliveira R, Santos UP. Hard metal lung disease: a case series. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2016 Nov-Dec:42(6):447-452. doi: 10.1590/S1806-37562016000000260. Epub [PubMed PMID: 28117477]
Level 2 (mid-level) evidenceSprince NL, Chamberlin RI, Hales CA, Weber AL, Kazemi H. Respiratory disease in tungsten carbide production workers. Chest. 1984 Oct:86(4):549-57 [PubMed PMID: 6434250]
Level 3 (low-level) evidenceSauni R, Linna A, Oksa P, Nordman H, Tuppurainen M, Uitti J. Cobalt asthma--a case series from a cobalt plant. Occupational medicine (Oxford, England). 2010 Jun:60(4):301-6. doi: 10.1093/occmed/kqq023. Epub 2010 Mar 22 [PubMed PMID: 20308255]
Level 2 (mid-level) evidenceEbert B, Jelkmann W. Intolerability of cobalt salt as erythropoietic agent. Drug testing and analysis. 2014 Mar:6(3):185-9. doi: 10.1002/dta.1528. Epub 2013 Aug 30 [PubMed PMID: 24039233]
Level 3 (low-level) evidenceCowie RM, Jennings LM. Third body damage and wear in arthroplasty bearing materials: A review of laboratory methods. Biomaterials and biosystems. 2021 Dec:4():100028. doi: 10.1016/j.bbiosy.2021.100028. Epub 2021 Sep 6 [PubMed PMID: 36824573]
Rivolta G, Nicoli E, Ferretti G, Tomasini M. Hard metal lung disorders: analysis of a group of exposed workers. The Science of the total environment. 1994 Jun 30:150(1-3):161-5 [PubMed PMID: 7939591]
de Moraes S, Mariano M. Biochemical aspects of cobalt intoxication. Cobalt ion action on oxygen uptake. Medicina et pharmacologia experimentalis. International journal of experimental medicine. 1967:16(5):441-7 [PubMed PMID: 6072255]
Level 3 (low-level) evidenceKRISS JP, CARNES WH, GROSS RT. Hypothyroidism and thyroid hyperplasia in patients treated with cobalt. Journal of the American Medical Association. 1955 Jan 8:157(2):117-21 [PubMed PMID: 13211322]
GARDNER FH. The use of cobaltous chloride in the anemia associated with chronic renal disease. The Journal of laboratory and clinical medicine. 1953 Jan:41(1):56-64 [PubMed PMID: 13023095]
Yang L, Wang D, Wang XT, Lu YP, Zhu L. The roles of hypoxia-inducible Factor-1 and iron regulatory protein 1 in iron uptake induced by acute hypoxia. Biochemical and biophysical research communications. 2018 Dec 9:507(1-4):128-135. doi: 10.1016/j.bbrc.2018.10.185. Epub 2018 Nov 8 [PubMed PMID: 30415773]
Fried W, Kilbridge T. Effect of testosterone and of cobalt on erythropoietin production by anephric rats. The Journal of laboratory and clinical medicine. 1969 Oct:74(4):623-9 [PubMed PMID: 5821519]
Level 3 (low-level) evidenceNemery B, Lewis CP, Demedts M. Cobalt and possible oxidant-mediated toxicity. The Science of the total environment. 1994 Jun 30:150(1-3):57-64 [PubMed PMID: 7939609]
Level 3 (low-level) evidenceMinang JT, Areström I, Troye-Blomberg M, Lundeberg L, Ahlborg N. Nickel, cobalt, chromium, palladium and gold induce a mixed Th1- and Th2-type cytokine response in vitro in subjects with contact allergy to the respective metals. Clinical and experimental immunology. 2006 Dec:146(3):417-26 [PubMed PMID: 17100760]
Packer M. Cobalt Cardiomyopathy: A Critical Reappraisal in Light of a Recent Resurgence. Circulation. Heart failure. 2016 Dec:9(12):. pii: e003604. Epub [PubMed PMID: 27852654]
Centeno JA, Pestaner JP, Mullick FG, Virmani R. An analytical comparison of cobalt cardiomyopathy and idiopathic dilated cardiomyopathy. Biological trace element research. 1996 Oct-Nov:55(1-2):21-30 [PubMed PMID: 8971351]
Level 2 (mid-level) evidenceRoy PE, Bonenfant JL, Turcot L. Thyroid changes in cases of Quebec beer drinkers myocardosis. American journal of clinical pathology. 1968 Aug:50(2):234-9 [PubMed PMID: 5673088]
Level 3 (low-level) evidenceForni A. Bronchoalveolar lavage in the diagnosis of hard metal disease. The Science of the total environment. 1994 Jun 30:150(1-3):69-76 [PubMed PMID: 7939611]
Cugell DW, Morgan WK, Perkins DG, Rubin A. The respiratory effects of cobalt. Archives of internal medicine. 1990 Jan:150(1):177-83 [PubMed PMID: 2297286]
Level 3 (low-level) evidenceDemedts M, Gheysens B, Nagels J, Verbeken E, Lauweryns J, van den Eeckhout A, Lahaye D, Gyselen A. Cobalt lung in diamond polishers. The American review of respiratory disease. 1984 Jul:130(1):130-5 [PubMed PMID: 6742597]
Level 3 (low-level) evidenceDai JH, Miao LY, Xiao YL, Meng FQ, Cai HR. [Giant cell interstitial pneumonia associated with hard metals: a case report and review of the literature]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2009 Jul:32(7):493-6 [PubMed PMID: 19954001]
Level 3 (low-level) evidenceNaqvi AH, Hunt A, Burnett BR, Abraham JL. Pathologic spectrum and lung dust burden in giant cell interstitial pneumonia (hard metal disease/cobalt pneumonitis): review of 100 cases. Archives of environmental & occupational health. 2008 Summer:63(2):51-70. doi: 10.3200/AEOH.63.2.51-70. Epub [PubMed PMID: 18628077]
Level 2 (mid-level) evidenceMoriyama H, Takada T, Aoki A, Shima K, Kikuchi T. Is giant cell interstitial pneumonia pathognomonic for hard metal lung diseases?-pathological and elemental analyses of 84 cases. Histopathology. 2025 Dec:87(6):923-932. doi: 10.1111/his.15537. Epub 2025 Aug 15 [PubMed PMID: 40815182]
Level 3 (low-level) evidenceFortarezza F, Perilli M, Della Barbera M, Pezzuto F, Faccioli E, Cocconcelli E, Cozzi E, Somigliana AB, Bonvicini B, Rea F, Basso C, Rizzo S, Calabrese F. Giant cell interstitial pneumonia: case series with comprehensive ultrastructural analyses of "not only" hard metal pneumoconiosis. Histopathology. 2025 Feb:86(3):450-459. doi: 10.1111/his.15335. Epub 2024 Oct 22 [PubMed PMID: 39438781]
Level 2 (mid-level) evidenceUde CC, Esdaille CJ, Ogueri KS, Ho-Man K, Laurencin SJ, Nair LS, Laurencin CT. The Mechanism of Metallosis After Total Hip Arthroplasty. Regenerative engineering and translational medicine. 2021 Sep:7(3):247-261. doi: 10.1007/s40883-021-00222-1. Epub 2021 Jul 29 [PubMed PMID: 35530571]
Dutta A, Nutt J, Slater G, Ahmed S. Review: Trunnionosis leading to modular femoral head dissociation. Journal of orthopaedics. 2021 Jan-Feb:23():199-202. doi: 10.1016/j.jor.2021.01.008. Epub 2021 Jan 30 [PubMed PMID: 33551613]
Watters TS, Cardona DM, Menon KS, Vinson EN, Bolognesi MP, Dodd LG. Aseptic lymphocyte-dominated vasculitis-associated lesion: a clinicopathologic review of an underrecognized cause of prosthetic failure. American journal of clinical pathology. 2010 Dec:134(6):886-93. doi: 10.1309/AJCPLTNEUAH8XI4W. Epub [PubMed PMID: 21088151]
Level 3 (low-level) evidenceGilbert CJ, Cheung A, Butany J, Zywiel MG, Syed K, McDonald M, Wong F, Overgaard C. Hip pain and heart failure: the missing link. The Canadian journal of cardiology. 2013 May:29(5):639.e1-2. doi: 10.1016/j.cjca.2012.10.015. Epub 2013 Jan 9 [PubMed PMID: 23313008]
Level 3 (low-level) evidenceCatalani S, Rizzetti MC, Padovani A, Apostoli P. Neurotoxicity of cobalt. Human & experimental toxicology. 2012 May:31(5):421-37. doi: 10.1177/0960327111414280. Epub 2011 Jul 5 [PubMed PMID: 21729976]
Zhong Q, Pan X, Chen Y, Lian Q, Gao J, Xu Y, Wang J, Shi Z, Cheng H. Prosthetic Metals: Release, Metabolism and Toxicity. International journal of nanomedicine. 2024:19():5245-5267. doi: 10.2147/IJN.S459255. Epub 2024 Jun 5 [PubMed PMID: 38855732]
Kent NL, McCance RA. The absorption and excretion of ;minor' elements by man: Cobalt, nickel, tin and manganese. The Biochemical journal. 1941 Sep:35(8-9):877-83 [PubMed PMID: 16747455]
Mosconi G, Bacis M, Vitali MT, Leghissa P, Sabbioni E. Cobalt excretion in urine: results of a study on workers producing diamond grinding tools and on a control group. The Science of the total environment. 1994 Jun 30:150(1-3):133-9 [PubMed PMID: 7939586]
Apostoli P, Porru S, Alessio L. Urinary cobalt excretion in short time occupational exposure to cobalt powders. The Science of the total environment. 1994 Jun 30:150(1-3):129-32 [PubMed PMID: 7939585]
Schirrmacher UO. Case of cobalt poisoning. British medical journal. 1967 Mar 4:1(5539):544-5 [PubMed PMID: 6017158]
Level 3 (low-level) evidenceLinna A, Oksa P, Palmroos P, Roto P, Laippala P, Uitti J. Respiratory health of cobalt production workers. American journal of industrial medicine. 2003 Aug:44(2):124-32 [PubMed PMID: 12874844]
HARDING HE. Notes on the toxicology of cobalt metal. British journal of industrial medicine. 1950 Apr:7(2):76-8 [PubMed PMID: 15414282]
Bradberry SM, Wilkinson JM, Ferner RE. Systemic toxicity related to metal hip prostheses. Clinical toxicology (Philadelphia, Pa.). 2014 Sep-Oct:52(8):837-47. doi: 10.3109/15563650.2014.944977. Epub 2014 Aug 16 [PubMed PMID: 25132471]
Apostoli P, Catalani S, Zaghini A, Mariotti A, Poliani PL, Vielmi V, Semeraro F, Duse S, Porzionato A, Macchi V, Padovani A, Rizzetti MC, De Caro R. High doses of cobalt induce optic and auditory neuropathy. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie. 2013 Sep:65(6):719-27. doi: 10.1016/j.etp.2012.09.006. Epub 2012 Oct 12 [PubMed PMID: 23069009]
Level 3 (low-level) evidenceKieć-Swierczyńska M. Occupational dermatoses and allergy to metals in Polish construction workers manufacturing prefabricated building units. Contact dermatitis. 1990 Jul:23(1):27-32 [PubMed PMID: 2144804]
Fritzsche J, Borisch C, Schaefer C. Case report: High chromium and cobalt levels in a pregnant patient with bilateral metal-on-metal hip arthroplasties. Clinical orthopaedics and related research. 2012 Aug:470(8):2325-31. doi: 10.1007/s11999-012-2398-0. Epub 2012 Jun 13 [PubMed PMID: 22692823]
Level 3 (low-level) evidenceVendittoli PA, Lavigne M, Roy AG. How do serum cobalt and chromium levels change after metal-on-metal hip resurfacing? Clinical orthopaedics and related research. 2006 Oct:451():292-3; author reply 293 [PubMed PMID: 16906090]
Level 3 (low-level) evidenceD'Adda F, Borleri D, Migliori M, Mosconi G, Medolago G, Virotta G, Colombo F, Seghizzi P. Cardiac function study in hard metal workers. The Science of the total environment. 1994 Jun 30:150(1-3):179-86 [PubMed PMID: 7939594]
Level 3 (low-level) evidenceAlexandersson R. Blood and urinary concentrations as estimators of cobalt exposure. Archives of environmental health. 1988 Jul-Aug:43(4):299-303 [PubMed PMID: 3415357]
Level 3 (low-level) evidenceIyengar V, Woittiez J. Trace elements in human clinical specimens: evaluation of literature data to identify reference values. Clinical chemistry. 1988 Mar:34(3):474-81 [PubMed PMID: 3280162]
Kwon YM, Della Valle CJ, Lombardi AV, Garbuz DS, Berry DJ, Jacobs JJ. Risk Stratification Algorithm for Management of Head-Neck Taper Tribocorrosion in Patients with Metal-on-Polyethylene Total Hip Arthroplasty: Consensus Statement of the American Association of Hip and Knee Surgeons, the American Academy of Orthopaedic Surgeons, and The Hip Society. The Journal of bone and joint surgery. American volume. 2021 Mar 3:103(5):e18. doi: 10.2106/JBJS.20.01837. Epub [PubMed PMID: 33411461]
Level 3 (low-level) evidenceSamar HY, Doyle M, Williams RB, Yamrozik JA, Bunker M, Biederman RWW, Shah MB. Novel Use of Cardiac Magnetic Resonance Imaging for the Diagnosis of Cobalt Cardiomyopathy. JACC. Cardiovascular imaging. 2015 Oct:8(10):1231-1232. doi: 10.1016/j.jcmg.2014.12.016. Epub 2015 Mar 18 [PubMed PMID: 25797125]
Level 3 (low-level) evidenceDu X, Liu J, Wang Y, Jin M, Ye Q. Cobalt-related interstitial lung disease or hard metal lung disease: A case series of Chinese workers. Toxicology and industrial health. 2021 May:37(5):280-288. doi: 10.1177/07482337211000989. Epub [PubMed PMID: 34078186]
Level 2 (mid-level) evidenceAdams TN, Butt YM, Batra K, Glazer CS. Cobalt related interstitial lung disease. Respiratory medicine. 2017 Aug:129():91-97. doi: 10.1016/j.rmed.2017.06.008. Epub 2017 Jun 13 [PubMed PMID: 28732841]
Ratto D, Balmes J, Boylen T, Sharma OP. Pregnancy in a woman with severe pulmonary fibrosis secondary to hard metal disease. Chest. 1988 Mar:93(3):663-5 [PubMed PMID: 3342680]
Level 3 (low-level) evidenceGiampreti A, Lonati D, Locatelli CA. Chelation in suspected prosthetic hip-associated cobalt toxicity. The Canadian journal of cardiology. 2014 Apr:30(4):465.e13. doi: 10.1016/j.cjca.2013.12.009. Epub 2013 Dec 17 [PubMed PMID: 24518658]
Level 3 (low-level) evidenceLlobet JM, Domingo JL, Corbella J. Comparative effects of repeated parenteral administration of several chelators on the distribution and excretion of cobalt. Research communications in chemical pathology and pharmacology. 1988 May:60(2):225-33 [PubMed PMID: 2839877]
Level 3 (low-level) evidenceDomingo JL, Llobet JM, Corbella J. The effects of EDTA in acute cobalt intoxication in rats. Toxicological European research. Recherche europeenne en toxicologie. 1983 Nov:5(6):251-5 [PubMed PMID: 6426088]
Level 3 (low-level) evidenceRizzetti MC, Liberini P, Zarattini G, Catalani S, Pazzaglia U, Apostoli P, Padovani A. Loss of sight and sound. Could it be the hip? Lancet (London, England). 2009 Mar 21:373(9668):1052. doi: 10.1016/S0140-6736(09)60490-6. Epub [PubMed PMID: 19304018]
Level 3 (low-level) evidenceCereda C, Redaelli ML, Canesi M, Carniti A, Bianchi S. Widia tool grinding: the importance of primary prevention measures in reducing occupational exposure to cobalt. The Science of the total environment. 1994 Jun 30:150(1-3):249-51 [PubMed PMID: 7939604]
Pelclova D, Sklensky M, Janicek P, Lach K. Severe cobalt intoxication following hip replacement revision: clinical features and outcome. Clinical toxicology (Philadelphia, Pa.). 2012 Apr:50(4):262-5. doi: 10.3109/15563650.2012.670244. Epub [PubMed PMID: 22455358]
Level 3 (low-level) evidenceLeikin JB, Karydes HC, Whiteley PM, Wills BK, Cumpston KL, Jacobs JJ. Outpatient toxicology clinic experience of patients with hip implants. Clinical toxicology (Philadelphia, Pa.). 2013 May:51(4):230-6. doi: 10.3109/15563650.2013.768343. Epub 2013 Feb 20 [PubMed PMID: 23421810]
Level 2 (mid-level) evidenceTower SS. Arthroprosthetic cobaltism: neurological and cardiac manifestations in two patients with metal-on-metal arthroplasty: a case report. The Journal of bone and joint surgery. American volume. 2010 Dec 1:92(17):2847-51. doi: 10.2106/JBJS.J.00125. Epub 2010 Oct 29 [PubMed PMID: 21037026]
Level 3 (low-level) evidenceCharette RS, Neuwirth AL, Nelson CL. Arthroprosthetic cobaltism associated with cardiomyopathy. Arthroplasty today. 2017 Dec:3(4):225-228. doi: 10.1016/j.artd.2016.11.005. Epub 2016 Dec 15 [PubMed PMID: 29204485]
Oldenburg M, Wegner R, Baur X. Severe cobalt intoxication due to prosthesis wear in repeated total hip arthroplasty. The Journal of arthroplasty. 2009 Aug:24(5):825.e15-20. doi: 10.1016/j.arth.2008.07.017. Epub 2008 Oct 2 [PubMed PMID: 18835128]
Level 3 (low-level) evidenceMariano A, Sartorelli P, Innocenti A. Evolution of hard metal pulmonary fibrosis in two artisan grinders of woodworking tools. The Science of the total environment. 1994 Jun 30:150(1-3):219-21 [PubMed PMID: 7939600]
Level 3 (low-level) evidenceMILLER CW, DAVIS MW, GOLDMAN A, WYATT JP. Pneumoconiosis in the tungsten-carbide tool industry; report of three cases. A.M.A. archives of industrial hygiene and occupational medicine. 1953 Nov:8(5):453-65 [PubMed PMID: 13091448]
Level 3 (low-level) evidenceSprince NL, Oliver LC, Eisen EA, Greene RE, Chamberlin RI. Cobalt exposure and lung disease in tungsten carbide production. A cross-sectional study of current workers. The American review of respiratory disease. 1988 Nov:138(5):1220-6 [PubMed PMID: 3264482]
Level 2 (mid-level) evidence. Correction to: Inhalation toxicity and carcinogenicity studies of cobalt sulfate. Toxicological sciences : an official journal of the Society of Toxicology. 2022 Jul 28:188(2):276. doi: 10.1093/toxsci/kfac063. Epub [PubMed PMID: 35726922]
Bucher JR, Hailey JR, Roycroft JR, Haseman JK, Sills RC, Grumbein SL, Mellick PW, Chou BJ. Inhalation toxicity and carcinogenicity studies of cobalt sulfate. Toxicological sciences : an official journal of the Society of Toxicology. 1999 May:49(1):56-67 [PubMed PMID: 10367342]
Level 3 (low-level) evidenceSuh M, Thompson CM, Brorby GP, Mittal L, Proctor DM. Inhalation cancer risk assessment of cobalt metal. Regulatory toxicology and pharmacology : RTP. 2016 Aug:79():74-82. doi: 10.1016/j.yrtph.2016.05.009. Epub 2016 May 10 [PubMed PMID: 27177823]